GMP synthesis of bulk drug substances. Task order no.75N95025F00001 (TO1), for synthesis of GMP psilocybin.
Ended Awarded Last action
- Contract number
- 75N95025F00001
- Awardee
-
Benuvia Operations, LLC UEI HY9DC6XAJFK3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $789,897
Award facts
- Opportunity
-
- GMP Synthesis of Bulk Drug Testing Pre-Solicitation · 75N95024R00058 · Posted Sep 1, 2023
- Contract value 100% obligated
- $789,896.88 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Round Rock, TX 78665, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Davis-Bacon Act FAR subpart 22.4
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | -$75,949 | |
| Original award | $865,845 |
About this award
The National Institute on Drug Abuse (NIDA) awarded a delivery order contract to Benuvia Operations, LLC on March 14, 2025, for the Good Manufacturing Practice (GMP) synthesis of bulk psilocybin drug substances. This task order (TO1) is valued at $789,897 and operates under a cost-plus-fixed-fee pricing structure. The work will be performed in Round Rock, Texas, with an ultimate completion date of March 13, 2030. No set-aside designation was used for this procurement.
This contract supports NIDA's mission to advance scientific understanding of drug abuse and addiction through research initiatives. The synthesis of GMP-compliant psilocybin falls within the agency's research mandate, particularly given increased scientific interest in investigating the potential therapeutic applications of psilocybin for certain mental health conditions. The cost-plus-fixed-fee arrangement allows flexibility in managing research and development activities while establishing predetermined overhead and profit margins.
Quick answers
Who was awarded contract 75N95025F00001?
75N95025F00001 was awarded to Benuvia Operations, LLC by National Institute on Drug Abuse (National Institutes of Health) on March 14, 2025.
How much is contract 75N95025F00001 worth?
The government has obligated $789,897 on 75N95025F00001.
Is contract 75N95025F00001 an order under another contract?
Yes. 75N95025F00001 is a delivery order under 75N95025D00003, an indefinite delivery contract.
Was contract 75N95025F00001 competed?
The extent of competition for 75N95025F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award